Reported Earlier, Cardiol Therapeutics Says First Patient Enrolled In Phase 2 Study Of CardiolRx For Pericarditis
Cardiol Therapeutics CEO David Elsley shared news the company has hit a major milestone in that the first patient has been enrolled in a Phase II open-label pilot study of CardiolRx in patients with recurrent pericarditis.